1. 1. Imyanitov, E. N., & Moiseenko, V. M. (2008). Primenenie molekulyarno-geneticheskogo analiza dlya vyibora protivoopuho- levoy terapii [Application of molecular genetic analysis for the selection of antitumor therapy]. Vopr. onkol. - Issues of oncology, 54 (2), 121-132 [in Ukrainian].
2. 2. Protsenko, S. A. (2012). Printsipyi individualizatsii lekarstvennoy terapii zlokachestvennyih opuholey [Principles of individualization of drug therapy of malignant tumors]. Extended abstract of Doctor's thesis. Saint Petersburg: NII onkologii im. N. N. Petrova [in Russian].
3. 3. Rak v Ukrayini 2014-2015: Byuleten natsionalnogo kantser-reestru Ukrayini [Cancer in Ukraine 2014-2015: Bulletin of the National Cancer Registry of Ukraine] (2016). FDUCh - FHDU, 17 [in Ukrainian].
4. C-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study;Fritz;Breast Cancer Research 7 (3),2005
5. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer;Şahin;Int J Surg Pathol 24 (7),2016